TL;DR:
- M42 introduces Med42, a groundbreaking Clinical Large Language Model (LLM) for healthcare.
- Med42 offers high-quality answers to medical queries and aims to enhance clinical decision-making.
- The model outperforms competitors and scores 72% on the USMLE Sample Exam.
- Developed in collaboration with Core42 and MBZUAI, Med42 is set to revolutionize healthcare.
- It functions as an AI assistant for healthcare professionals, aiding in treatment planning and research.
- Med42 is available for download on Hugging Face for non-commercial use, with appropriate controls.
- The model’s fine-tuning utilized Cerebras and G42’s Condor Galaxy 1 supercomputer.
- M42’s strategic position and expertise in genomics and AI position it as a leader in healthcare innovation.
Main AI News:
M42, the global tech-enabled healthcare network, has unleashed Med42, a monumental Clinical Large Language Model (LLM). This 70 billion-parameter generative artificial intelligence (AI) marvel is set to reshape the future of AI applications in healthcare, promising profound impacts on patient care outcomes.
Med42 emerges as a potent solution, delivering impeccable responses to both concise and in-depth medical inquiries. Its development aims to exponentially elevate clinical decision-making, while also democratizing access to synthesized medical knowledge across the spectrum of healthcare stakeholders – from professionals and patients to researchers and regulators.
A product of rigorous training on M42’s meticulously curated medical dataset, Med42 exhibits its prowess by outperforming larger closed models in various healthcare-related datasets. Notably, it shines with flying colors, scoring a remarkable 72% in a zero-shot evaluation on the United States Medical Licensing Examination (USMLE) Sample Exam questions, leaving competitors like ChatGPT 3.5 in its wake.
Crafted by M42’s dedicated team based in Abu Dhabi, Med42 underwent meticulous fine-tuning in collaboration with Core42, a G42 company dedicated to national-scale AI and Enterprise AI initiatives, utilizing Cerebras technology. To ensure the model’s precision, experts from Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) meticulously evaluated its performance.
Hasan Jasem Al Nowais, Managing Director and Group Chief Executive Officer of M42, elucidated, “Med42 marks a pivotal milestone in global healthcare knowledge accessibility, epitomizing our unwavering commitment to catalyzing transformative change in the healthcare sector. M42 stands at the forefront of healthcare innovation, charting a course towards more personalized, patient-centric care. Our unique blend of top-tier healthcare expertise and cutting-edge technology empowers us to significantly contribute to the future of AI in healthcare – a future characterized by universal accessibility, ethical grounding, and user safety.”
Al Nowais further affirmed, “The debut of Med42 firmly cements the United Arab Emirates’ esteemed status in the global generative AI domain. We extend our gratitude to the Abu Dhabi Department of Health and the broader technology ecosystem in Abu Dhabi for their invaluable support.“
Med42’s potential extends beyond imagination, serving as an indispensable AI assistant for healthcare professionals. It excels at formulating tailored treatment plans by scrutinizing a patient’s medical history, ensuring the most optimal course of action. Moreover, it expedites access to insights for doctors, guides pharmacists in determining precise dosages, and provides invaluable support to scientists engaged in the exploration of treatment options, enhancing their ability to efficiently review literature.
In a bid to foster collaboration and enhance the capabilities of this generative AI model, Med42 is readily available for download on Hugging Face, inviting extensive testing, review, and assessment by the scientific and developer community. Mirroring the licensing terms of Meta’s Llama 2 model, Med42 is freely accessible for non-commercial purposes and research, subject to appropriate controls to mitigate the inherent risks of deploying AI in healthcare settings.
Ashish Koshy, Group Chief Operating Officer of M42, emphasized, “Innovation transcends technological prowess; it is fundamentally rooted in delivering solutions that have a tangible, positive impact on real-world challenges. Med42 is not merely a tool; it represents a platform for collaborative advancement. M42 aspires to be the catalyst for global AI innovation in healthcare, empowering experts worldwide to refine and broaden the model’s applications across diverse medical domains. Our strategic partnerships with technology leaders, including Cerebras, enable us to transform this vision into reality and realize our long-term transformative objectives.“
The full-parameter fine-tuning of the colossal Llama 2 model was executed with precision on Cerebras and G42’s Condor Galaxy 1 (CG-1) AI supercomputer. With an astounding 82 terabytes of memory and an array of 54 million AI cores spread across 64 Cerebras CS-2 systems within CG-1, the setup expedited the process, minimizing training time and maximizing efficiency.
Andrew Feldman, co-founder and Chief Executive Officer of Cerebras Systems, lauded the strategic partnership with G42 and its portfolio companies, stating, “Our collaboration has been designed to reshape the AI landscape. It has already yielded Condor Galaxy 1, the world’s largest AI supercomputer, and Jais, the leading Arabic LLM, for the global community. Today, we take pride in ushering in another state-of-the-art LLM, Med42, offering immense benefits to the healthcare arena.”
M42’s unparalleled position at the helm of healthcare transformation is underscored by its unmatched access to medical and data-centric technologies, encompassing genomics and AI. Paired with a comprehensive portfolio of world-class patient services and a network of cutting-edge facilities, M42 is primed to deliver the pinnacle of personalized, precise, and preventive care.
Conclusion:
M42’s Med42 heralds a transformative era in healthcare AI, promising to revolutionize clinical decision-making, accessibility to medical knowledge, and personalized patient care. This innovation positions M42 as a leader in the global generative AI landscape, with potentially far-reaching implications for the healthcare market’s future.
